Vivoryon Therapeutics NV 2020 AR2
The report outlines Vivoryon Therapeutics N.V.'s clinical and operational progress for the fiscal year 2020, highlighted by the initiation of the Phase 2b VIVIAD trial in Europe for its lead Alzheimer's candidate, varoglutamstat. The company successfully converted into a Dutch N.V. to enhance strategic flexibility and global investor appeal. Financially, Vivoryon reported a net loss of EUR 16.5 million, with research and development expenses increasing to EUR 13.2 million to support its expanding clinical pipeline. The company also broadened its pipeline by acquiring patents for Meprin protease inhibitors to target indications like fibrosis and cancer.
Company: Vivoryon Therapeutics NV
Sector: Health Care
Country: Germany
Year: 2020
Type: AR2
Pages: 108
Vivoryon Therapeutics NV
Annual Report
The report outlines Vivoryon Therapeutics N.V.'s clinical and operational progress for the fiscal year 2020, highlighted by the initiation of the Phase 2b VIVIAD trial in Europe for its lead Alzheimer's candidate, varoglutamstat. The company successfully converted into a Dutch N.V. to enhance strategic flexibility and global investor appeal. Financially, Vivoryon reported a net loss of EUR 16.5 million, with research and development expenses increasing to EUR 13.2 million to support its expanding clinical pipeline. The company also broadened its pipeline by acquiring patents for Meprin protease inhibitors to target indications like fibrosis and cancer.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees